1. France Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Ikonisys SA

Ikonisys SA

EEURONEXT:ALIKO
1.37
EUR
-0.01
(-0.72%)
25.32MMarket Cap
Mar 03Next Earn
Ikonisys SA
EURONEXT:ALIKO
(Euronext)

Recent

price

1.37

P/E

ratio

- -

div

yld

- -

ROIC.AI

2019
2020
2021
2022
2023
2024
2025
TTM
EUR
0.06
0.04
0.04
0.07
0.05
0.09
0.1
- -
Revenue per Share
-0.13
-0.16
-0.06
-0.26
-0.23
-0.29
-0.3
- -
Basic EPS, GAAP
- -
-0.16
-0.14
-0.21
-0.15
-0.11
-0.1
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.63
0.59
2.11
1.86
1.61
1.27
1.21
1.21
Book Value per Share
-0.19
-0.24
-0.06
-0.32
-0.43
-0.98
-0.25
-0.25
Tangible Book Value per Share
10
10
9
9
10
11
14
15
Basic Weighted Avg Shares
1
- -
- -
1
- -
1
1
- -
Sales/Revenue/Turnover
48.3
27.22
-203.15
-446.31
-532.9
-303.08
-290.72
- -
Operating Margin (%)
- -
- -
- -
1
1
1
3
- -
Depreciation Expense
-1
-2
-1
-2
-2
-3
-4
- -
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-204.22
-408.02
-156.45
-396.9
-505.54
-317.29
-302.84
- -
Profit Margin (%)
-2
-2
1
-1
-1
-9
-3
-3
Working Capital
- -
- -
- -
1
2
2
2
2
LT Debt
6
6
20
18
16
14
19
19
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
-26.68
-4.44
-12.99
-13.58
-21.61
-25.18
- -
Return on Common Equity (%)

Capital Structure

EUR

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
ST Debt
2
- -
1
LT Borrowings
2
3
1
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
11
14
16
Market Capitalization
17
21
25

Working Capital

EUR

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
Total Current Assets
2
1
3
Cash, Cash Equivalents & STI
- -
- -
1
Accounts Receivable, Net
1
1
- -
Inventories
1
1
1
Total Current Liabilities
10
3
6
Payables & Accruals
- -
- -
- -
ST Debt
2
- -
1
Deferred Revenue
- -
- -
- -

Growth Rates

EUR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
50.67%
34.25%
Free Cash Flow
- -
1.81%
13.06%
Net Income, GAAP
- -
66.03%
29.74%
Sales/Revenue/Turnover
- -
40%
35.93%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
1
2025
- -
- -
1

Semi-annual Earnings Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
-0.23
2024
- -
- -
-0.29
2025
- -
- -
-0.3

Semi-annual Dividends Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
Medtronic plc. (NYSE:MDT)
Business
Ikonisys S.A. (Euronext Growth Paris: ALIKO), now operating under the ALIKO SCIENTIFIC brand, specializes in the design, manufacture, and marketing of automated medical diagnostic equipment for oncology and cell-based diagnostics. The company offers advanced fluorescence in situ hybridization (FISH) platforms including Ikoniscope robotic microscopy systems, Ikoniscope20, and Ikoniscope Max for automated imaging and AI-enhanced analysis; cell diagnostic products for cancer diagnosis (such as oncoFISH applications for bladder, breast HER2, cervical, prostate PTEN, lung ALK, and hematological cancers), genetic disorder detection, fertility testing, and circulating tumor cell (CTC) detection; precision cytology solutions through subsidiary Hospitex International Srl featuring Cytofast cytology systems for sample preparation and standardization. Founded in 1999 with U.S. roots in New Haven, Connecticut, Ikonisys S.A. was incorporated in France in 2021 and maintains headquarters at 62 Rue de Caumartin in Paris; it operates globally with subsidiaries Ikonisys Inc. in the United States and Hospitex in Italy (Milan), targeting oncology diagnostic laboratories, medical analysis labs, and healthcare providers in Europe and North America. Recent developments include the full acquisition of Hospitex International Srl in April 2024 for €4.5 million (with potential additional €1.125 million earn-out by June 2025), finalized via issuance of 2 million new shares in December 2024; rebranding to ALIKO SCIENTIFIC in December 2024 with a new strategy emphasizing product integration for tumor-specific solutions, global commercial expansion, and technology scouting; multiple capital increases totaling €2.2 million in 2024; partnerships such as distribution agreements with Menarini Diagnostics Italy and BioBrasil; and renewed ISO 13485 certification, driving FY2024 net sales to €1.01 million.